The scrip gained 7.81 per cent to Rs 546.70 – its 52-week high – on BSE.
On NSE, it jumped 7.74 per cent to touch 1-year high of Rs 546.90.
In a BSE filing, the company said: “It has received abbreviated new drug application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil tablets of AstraZeneca.”
As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids, of which 578 have been approved in various regions globally.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)